Latest News

STAT Plus: Trump proposal to shift Part B drugs to Part D would hurt most beneficiaries, analysis says

One of the many proposals the Trump administration is kicking around in order to lower drug costs would shift coverage of some medicines from Medicare Part B to Part D, which is administered by private managed care plans. A new analysis, however, cautions that while government spending might be reduced, the proposal may also increase out-of-pocket costs for some beneficiaries.

How so? Let’s start at the beginning: Part B drugs are often high-priced and mostly administered by infusion or injection in physician offices. Part D drugs are purchased from pharmacies. But there is another key difference: Managed care plans can negotiate prices for Part D drugs. This is why the administration is considering moving coverage for some drugs from Part B to Part D.

Continue to STAT Plus to read the full story…

Source link

Related posts

Request for applications: Community Leadership Institute of Kentucky


A mixed methods exploration of the role of friends and identity in multiracial adolescent girls' mental health


STAT Plus: Here are five immediate takeaways from Roche’s $5 billion acquisition of Spark Therapeutics


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy